Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia
Fang Cheng,1,2 Zheng Cui,1,2 Qiang Li,1,2 Liu Wang,1,2 Yu Zhang,1,2 Weiming Li3 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China; 2Hubei Province Clinical Research Center for Precision Medicine f...
Saved in:
| Main Authors: | Cheng F, Cui Z, Li Q, Wang L, Zhang Y, Li W |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-05-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/dasatinib-dose-optimization-based-on-therapeutic-drug-monitoring-in-pa-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Gelatinous Marrow Transformation in Chronic Myeloid Leukemia Post-Dasatinib Treatment: A Case Report with Review of Literature
by: Gayathri Kini, et al. -
Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life
by: TI Ionova, et al.
Published: (2017-04-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Chen J, et al.
Published: (2025-07-01)